Related Experiment Video

Updated: Jul 18, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Achieving white blood cell equity: are the safety profiles of biosimilar and reference pegfilgrastims comparable?

Arturo Loaiza-Bonilla1, Ray D Page2

  • 1Capital Health Cancer Center, Hopewell, NJ 08534, USA.

Future Oncology (London, England)
|August 23, 2023
PubMed

Keywords:
adverse eventbiologicbiosimilarfebrile neutropeniapegfilgrastimsafety

More Related Videos

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

661
Evaluation of a Point-of-Care Testing Analyzer for Measuring Peripheral Blood Leukocytes05:58

Evaluation of a Point-of-Care Testing Analyzer for Measuring Peripheral Blood Leukocytes

Published on: March 22, 2022

4.1K

Related Concept Videos

Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K